Kunming Saino Pharmaceutical

Kunming Saino Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and manufacturing of modern Chinese medicines and chemical drugs. The company focuses primarily on cardiovascular and cerebrovascular health, with a product portfolio that includes treatments for hypertension, coronary heart disease, and cerebral infarction. Established in the Kunming High-tech Zone, it integrates traditional herbal knowledge with modern pharmaceutical technology. Saino is recognized for its high-tech manufacturing capabilities and its commitment to the modernization of Traditional Chinese Medicine (TCM). The company's flagship products are derived from Erigeron breviscapus, a herb native to the Yunnan plateau. Kunming Saino operates extensive GMP-certified production lines for various dosage forms including capsules, tablets, and injections.